{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.1","upperLimit":"69.8","value":"51.6"},{"groupId":"OG001","lowerLimit":"58.9","upperLimit":"90.4","value":"77.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\\]). Disease Control rate per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenvatinib (lenva) 20 mg via oral capsule once a day (QD) up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG000","title":"Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG001","title":"Cohort B: Ovarian Cancer (Lenva + Pembro)"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}